Wanbury Ltd Stock Price Today (NSE: WANBURY)

Wanbury Ltd

267.950.55 (0.20%)
Market Closed

Fundamental Score

...

Wanbury Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis

Wanbury Ltd share price today is 267.95, down 0.20% on NSE/BSE as of 17 June 2026. Wanbury Ltd (WANBURY) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of 895.00 (Cr). The 52-week high for WANBURY share price is 314.90 and the 52-week low is 161.50. At a P/E ratio of 20.82x, WANBURY is currently trading below its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 76.52% and a debt-to-equity ratio of 3.02.

Wanbury Ltd Share Price Chart — NSE/BSE Historical Performance

No data
High
277.65
Low
234.00
Volume
47.2K
Change
+3.48%

Wanbury Ltd share price chart: 3.48% return over the past month. 52-week high ₹314.90, 52-week low ₹161.50.

Wanbury Ltd — Last 10 Trading Days

DateOpenHighLowCloseVolume
252.65261.55249.10260.6069.78K (Cr)
259.95262.90246.60249.1051.98K (Cr)
256.50263.00249.90257.3561.93K (Cr)
253.30256.00250.10253.0512.26K (Cr)
256.50257.50249.00253.3541.39K (Cr)
250.15257.95247.00252.8533.71K (Cr)
250.60254.70244.15250.4545.51K (Cr)
253.95264.50250.00253.5032.35K (Cr)
259.80259.80253.03254.2819.17K (Cr)
261.00264.00255.20257.9639.48K (Cr)

Wanbury Ltd — Last 12 Months Price History

MonthOpenHighLowCloseChange
253.95264.50244.15260.60+2.62%
232.87277.65220.50254.28+9.19%
252.40265.35217.95221.95-12.06%
205.30284.00203.61265.61+29.38%
225.25238.00161.50208.75-7.33%
258.20263.90225.00226.60-12.24%
260.05274.20222.75260.25+0.08%
257.05270.00222.00262.85+2.26%
278.50288.45244.10254.50-8.62%
266.00309.00247.30278.30+4.62%
281.00289.00235.40268.90-4.31%
313.00320.95265.00280.50-10.38%

Returns & Performance

Excellent

Return on Equity (ROE)

76.52%

Profit generated per ₹1 of shareholder equity

Excellent

Return on Capital (ROCE)

36.68%

Returns generated on total capital deployed

Poor

Oper. Profit Margin (5Y Avg)

9.18%

Average operating profit margin over 5 years

Dividend Yield

0.00%

Annual dividend as % of current share price

Wanbury Ltd Valuation Check

Excellent

Price to Earnings (P/E)

20.82x

Share price ÷ earnings per share. Lower = cheaper

Poor

Industry Avg P/E

31.77x

Average P/E of all peers in this sector

Market-cap Classification
Small-cap
Higher growth potential with higher volatility.

Shareholding Pattern

Excellent

Promoter Holding

39.63%

% shares held by company founders/management

Poor

FII Holding

0.80%

% shares held by foreign institutional investors

Poor

DII Holding

0.00%

% held by domestic mutual funds, LIC, banks

Poor

Promoter Pledged %

71.73%

% of promoter shares pledged as collateral — lower is safer

Growth Engine

Excellent

Profit Growth (Quarterly YoY)

1197.12%

Net profit growth vs same quarter last year

Excellent

Revenue Growth (Quarterly YoY)

24.46%

Revenue growth vs same quarter last year

Average

Revenue Growth (5-Year CAGR)

10.29%

Compounded annual revenue growth over 5 years

Excellent

EPS Growth (5-Year CAGR)

27.81%

Earnings per share growth over 5 years

Excellent

Net Profit Growth (5-Year CAGR)

30.94%

Compounded annual net profit growth over 5 years

Balance Sheet Health

Poor

Debt to Equity Ratio

3.02x

Total debt ÷ equity. Below 0.5 = financially healthy

Poor

Interest Coverage Ratio

2.14x

EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably

Free Cash Flow (5-Year Total)

29.50 (Cr)

Cash left after capex over 5 years. Positive = self-funded growth

Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice

Wanbury Ltd Fundamental Analysis & Valuation Benchmarking

Educational evaluation of WANBURY across key market metrics for learning purposes.

Positive Indicators

8 factors identified

Strong Return on Equity (76.52%)

Observation: Efficient use of shareholders' capital generating superior returns.

Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.

Excellent ROCE Performance (36.68%)

Observation: Superior returns on capital employed across business operations.

Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.

Attractive Valuation (P/E: 20.82 vs Industry: 31.77)

Observation: Trading at discount to industry peers.

Analysis: P/E below industry average may present value opportunity.

Robust Profit Growth (1197.12%)

Observation: Strong year-over-year profit expansion demonstrates business momentum.

Analysis: Profit growth >20% indicates effective execution and market opportunity capture.

Strong Revenue Growth (24.46%)

Observation: Healthy sales growth indicates market demand and execution capability.

Analysis: Revenue growth >15% suggests strong market position and growth potential.

Excellent EPS Growth (27.81% CAGR)

Observation: Outstanding 5-year earnings per share compound growth.

Analysis: EPS CAGR >15% indicates strong wealth creation potential.

Strong Profit Growth Track Record (30.94% CAGR)

Observation: Consistent 5-year profit compound annual growth rate.

Analysis: Profit CAGR >15% demonstrates scalable business model.

Strong Cash Generation (₹29.50 Cr over 5Y)

Observation: Healthy free cash flow generation supports growth and returns.

Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.

Risk Factors

5 factors identified

Elevated Debt Levels (D/E: 3.02)

Observation: High leverage increases financial risk and interest burden.

Analysis: High debt-to-equity ratios require monitoring of debt servicing capability.

Weak Interest Coverage (2.14x)

Observation: Limited ability to service debt obligations from earnings.

Analysis: Low interest coverage raises concerns about financial stability.

Limited Institutional Interest (FII+DII: 0.80%)

Observation: Low institutional participation may affect liquidity.

Analysis: Limited institutional interest may indicate size constraints or visibility issues.

High Share Pledging Risk (71.73%)

Observation: Significant promoter share pledging creates potential overhang.

Analysis: High pledging levels may create selling pressure during market downturns.

No Dividend Distribution

Observation: Company does not currently pay dividends to shareholders.

Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.

Wanbury Ltd vs Pharmaceuticals Peers

Peer Comparison - Pharmaceuticals

Compare Wanbury Ltd with 10 other companies in the same sector

11 companies
Company Info
Fundamental
Valuation
Profitability
Financial Health
Growth
Dividend
Company
Company name
Score
Bull Run comprehensive fundamental score based on 20+ metrics
Price
Current trading price of the stock
Market Cap
Total value of all shares in the market
P/E
Price per share divided by earnings per share
ROE
Net income divided by shareholder equity
ROCE
Earnings before interest and tax divided by capital employed
Debt/Eq
Total debt divided by total equity
Profit 5Y
Average annual profit growth over 5 years
Sales 5Y
Average annual sales growth over 5 years
Dividend
Annual dividend per share divided by price per share
37.6/100
268
₹895.00
20.8
Average
76.52%
Excellent
36.68%
Excellent
3.0
Poor
30.94%
Excellent
10.29%
Good
0.00%
65.2/100
1844
₹433738.68
37.6
Average
16.86%
Good
20.21%
Excellent
0.1
Excellent
23.78%
Excellent
9.87%
Good
0.89%
67.9/100
6798
₹170445.88
68.6
Average
15.35%
Good
20.44%
Excellent
0.0
Excellent
10.41%
Good
11.65%
Good
0.47%
65.3/100
4538
₹126430.62
58.4
Average
26.52%
Excellent
27.05%
Excellent
0.3
Excellent
13.84%
Good
7.72%
Good
0.86%
Cipla Ltd...
CIPLA500087
59/100
1418
₹123059.76
22.6
Average
17.77%
Good
22.72%
Excellent
0.0
Excellent
28.68%
Excellent
9.97%
Good
0.85%
59.2/100
1319
₹105224.96
18.2
Average
17.96%
Good
22.69%
Excellent
0.2
Excellent
22.28%
Excellent
13.26%
Good
0.63%
Lupin Ltd...
LUPIN500257
66.7/100
2276
₹95148.15
22.0
Average
20.62%
Excellent
21.30%
Excellent
0.3
Excellent
54.88%
Excellent
8.11%
Good
0.58%
68.7/100
957
₹94253.78
18.7
Average
21.21%
Excellent
24.31%
Excellent
0.4
Excellent
25.92%
Excellent
10.27%
Good
1.17%
50.6/100
2420
₹92012.53
52.6
Average
14.68%
Average
15.98%
Good
0.6
Good
11.73%
Good
15.79%
Excellent
0.04%
28.8/100
1436
₹70798.69
20.7
Average
11.08%
Average
14.18%
Average
0.2
Excellent
3.87%
Average
6.55%
Good
0.33%
59.5/100
5452
₹67075.29
28.5
Average
19.39%
Good
20.38%
Excellent
0.2
Excellent
13.93%
Good
9.21%
Good
0.80%

Wanbury Ltd PE Ratio History

Historical price-to-earnings ratio for WANBURY — last 5 years

YearEPS (₹)Price (₹)P/E Ratio
FY 20258.98₹226.6025.2x
FY 202416.89₹291.1817.2x
FY 202225.21₹49.001.9x

P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.

Wanbury Ltd Quarterly Performance

Latest quarterly metrics for WANBURY — revenue growth and profit growth vs same quarter last year

Revenue Growth (YoY)

24.46%

Latest quarter vs same quarter previous year

Net Profit Growth (YoY)

1197.12%

Latest quarter net profit vs same quarter previous year

5-Year Revenue CAGR

10.29%

Compounded annual revenue growth over 5 years

5-Year Profit CAGR

30.94%

Compounded annual net profit growth over 5 years

Wanbury Ltd Technical Indicators

SMA 50, SMA 200, RSI and volume signals for WANBURY — calculated from daily price history

41RSI 14
Neutral — RSI 41

Momentum is balanced — neither overbought nor oversold.

SMA 50
249
▲ Price above SMA 50 — Short-term bullish
SMA 200
247
▲ Price above SMA 200 — Long-term uptrend
30-Day Avg Volume
49K shares/day
Average daily traded volume over last 30 trading sessions

Technical indicators are for educational purposes only. Not investment advice.

Wanbury Ltd Financial Statements

Annual income statement, balance sheet and cash flow for Wanbury Ltd (WANBURY) — sourced from NSE/BSE filings.

Loading Financial Statements...

Fetching financial data for Wanbury Ltd

About WANBURY (Wanbury Ltd)

Wanbury Ltd is a pharmaceutical company driven by innovation and a commitment to improving healthcare outcomes across the globe. The company formulates, develops, manufactures, and... markets a diverse portfolio of pharmaceutical products including formulations and active pharmaceutical ingredients (APIs). Wanbury addresses a range of therapeutic areas, providing solutions for common and complex health challenges. With a dedication to quality and patient well-being, the company strives to deliver effective and accessible medicines that enhance the lives of people worldwide. Wanbury's integrated approach encompasses research and development, manufacturing excellence, and strategic partnerships, all of which contribute to its sustained growth and success in the competitive pharmaceutical landscape. Wanbury's formulation offerings cover a wide range of medical needs, from managing common ailments to addressing more specialized conditions. Its anti-infective range battles bacterial and viral infections, while its pain and analgesics provide relief for various types of discomfort. Wanbury's product lineup also includes formulations for respiratory conditions, gastroenterological disorders, gynecological health, rheumatological issues, and central nervous system disorders. The company understands the importance of overall health and well-being, and it also provides a comprehensive range of vitamins, minerals, and nutritional supplements. By addressing diverse therapeutic needs, Wanbury plays a vital role in promoting health and improving the quality of life for patients across different demographics. Wanbury's API division plays a crucial role in the pharmaceutical supply chain, providing essential ingredients for a variety of medications. The company manufactures APIs for antidiabetics, helping to manage blood sugar levels in diabetic patients. It also produces APIs for antihistamines, offering relief from allergy symptoms, and for antitussives, which alleviate coughs. Wanbury's API portfolio extends to analgesics, antidepressants, and anti-inflammatory medicines, supporting the production of drugs that address pain, mood disorders, and inflammation. Through its commitment to quality and reliability, Wanbury contributes to the availability of effective and affordable medications, empowering healthcare professionals and patients alike.

Company Details

Symbol:WANBURY
Industry:Pharmaceuticals
Sector:Pharmaceuticals

Key Leadership

Mr. Mohan Kumar Rayana
Whole Time Director
Mr. Vinod R. Verma
Chief Financial Officer
Mr. Jitendra Jayantilal Gandhi
Compliance Officer & Company Secretary

Corporate Events

Recent
Ex-Dividend Date

WANBURY Share Price: Frequently Asked Questions

What is the current share price of Wanbury Ltd?

Wanbury Ltd (WANBURY) trades at ₹267.95 on NSE and BSE. Market cap ₹895.00 (Cr). Educational data only.

What is the P/E ratio of Wanbury Ltd?

Wanbury Ltd has a P/E of 20.82x vs industry average 31.77x.

What is the Bull Run score for Wanbury Ltd?

Wanbury Ltd has a Bull Run score of 37.6/100 based on 25+ financial parameters.

Does Wanbury Ltd pay dividends?

Wanbury Ltd has a dividend yield of 0.00%. Past dividends don't guarantee future payments.

What is the ROE of Wanbury Ltd?

Wanbury Ltd has ROE of 76.52%. Higher ROE indicates better use of shareholder equity.

What is the debt-to-equity ratio of Wanbury Ltd?

Wanbury Ltd has debt-to-equity of 3.02.

Is Wanbury Ltd a good investment?

Bull Run gives Wanbury Ltd a score of 37.6/100. This is not investment advice — consult a SEBI-registered advisor.